Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Status: Active


This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.

Eligibility Criteria

Inclusion Criteria

  • Signed written informed consent.
  • Age ≥ 18 years old.
  • Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric adenocarcinoma.
  • HER2+ as 3+ by IHC or in-situ hybridation (ISH) amplified.
  • Have received prior treatment with trastuzumab.
  • Have received treatment with at least one or more lines of cytotoxic chemotherapy in the metastatic setting.
  • Resolution of chemotherapy, immunotherapy or radiation-related toxicities.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy ≥ 12 weeks.
  • Measurable disease as per RECIST 1.1 criteria.
  • Archival or newly obtained tissue sample of a tumor lesion.
  • Adequate organ function as determined by following laboratory parameters:
  • Heme: Plt Ct ≥ 100 x 103/µL, ANC ≥ 1.5 x 103/µL, and Hemoglobin ≥ 9 g/dL
  • Chemistry: ALT/AST ≤ 3.0 x ULN, TBili ≤1.5 x ULN, and Cr < 2 mg/dL
  • Female patients of childbearing potential must have a negative pregnancy test and agree to use two forms of acceptable contraceptive measures from the time of consent through 120 days after discontinuation of study drug administration.
  • Male patients with partners of childbearing potential must use barrier contraception.

Exclusion Criteria

  • Patients with symptomatic central nervous system (CNS) metastases.
  • Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.
  • History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
  • Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 3 weeks prior to the initiation of study drug.
  • Treatment with radiation therapy within 3 weeks prior to the initiation of study drug administration.
  • Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.
  • History of clinically-significant cardiovascular disease.
  • Clinically-significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.
  • Presence of active pneumonitis
  • Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.
  • Evidence of active viral, bacterial, or systemic fungal infection.
  • Known positive testing for human immunodeficiency virus (HIV)or history of acquired immune deficiency syndrome (AIDS).
  • Known history of or positive test for hepatitis B or hepatitis C infection.
  • Second primary invasive malignancy that has not been in remission for greater than 2 years.
  • Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug or vehicle formulation for margetuximab or pembrolizumab.
  • Female patient who is breastfeeding.

Locations & Contacts


New Haven
Yale University
Status: Active
Name Not Available

District of Columbia

MedStar Georgetown University Hospital
Status: Active
Name Not Available


Beth Israel Deaconess Medical Center
Status: Approved
Name Not Available
Brigham and Women's Hospital
Status: Active
Name Not Available
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available

North Carolina

Duke University Medical Center
Status: Active
Name Not Available


Fox Chase Cancer Center
Status: Active
Name Not Available

Trial Objectives and Outline

Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will evaluate safety of escalating doses of the combination treatment. The Dose Expansion phase will evaluate safety and activity of the combination once the final dose and schedule are defined.

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type


Lead Organization

Lead Organization
MacroGenics Inc

Trial IDs

Primary ID CP-MGAH22-05
Secondary IDs NCI-2016-00290 ID NCT02689284